Seegene marks new milestone in popularization of molecular diagnostic technology
Seegene Inc., South Korea’s largest point-of-service diagnostic kit manufacturer, will mark another milestone in popularizing molecular diagnostic technology with an advanced polymerase chain reaction (PCR) machine in time. real to detect various viruses, including Covid variants in the clinical ward, helping authorities respond more quickly to the spread of the virus.
The new test called AIOS will be presented for the first time at the opening of the American Association for Clinical Chemistry (AACC) to be held in Atlanta from September 26 to 30, according to sources close to the company on Thursday.
The AACC houses the latest technology and information on various diagnostic equipment, reagents, and test methods. Seegene, whose annual sales reached $ 1 billion last year, is one of the most notable companies among this year’s AACC presenters.
According to the sources, AIOS can perform the entire process of molecular diagnostics, such as nucleic acid extraction, PCR testing, and reading of results, with one system after sample collection.
Depending on the type of reagents, AIOS can detect up to 10 types of viruses including Covid-19 variants at the same time, or up to 15 types of respiratory viruses except Covid viruses. It weighs about a third less than the bulky all-in-one PCR equipment that weighs 1 to 1.5 tonnes. The new equipment comes in the form of a separate set into two compact devices to allow transport and installation in small clinics.
Sales are expected to start worldwide at the start of the new year. Seegene will mark its 20th anniversary with the launch of AIOS which will make advanced molecular diagnostics available in most small and medium-sized hospitals and neighborhood clinics which account for 39% of patient beds compared to 9% of large hospitals in Korea, according to the sources.
By Kim Si-gyun and Minu Kim
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]